Peak by the Shanghai listed companies "gold quality" award
Release time:
2020-07-22
Peak Won the "Gold Quality" Award of Shanghai Listed Company
is Jinhua's only listed company
to win this award. News from our newspaper 12# November 13 , the "2019 High-quality Development Forum of listed companies" and the "Golden quality" award ceremony sponsored by Shanghai Securities News was held in the trading hall of Shanghai Stock Exchange. Jianfeng Group was awarded the "Golden Quality" Sustainable Growth Award for listed companies on the Shanghai Stock Exchange at this ceremony. It is the only listed company in Jinhua that has won this award.
Listed companies are the backbone of China's economy, and the quality of listed companies is the cornerstone of the sustainable development of the capital market. In the process of building a modern economic system and achieving high-quality development, listed companies should give full play to the "head goose" effect. To adhere to high-quality development, we should constantly improve the "hard technology" of listed companies, constantly strengthen the "hard governance" of listed companies, and constantly enhance the "hard skills" of high-quality development ". Taking this as a starting point, this forum takes "Innovating Chinese Values and Building Chinese Power" as the theme, and the "Golden Quality" award selection has three categories and ten awards: "Company Award", "Entrepreneur Award" and "Secretary of the Board Award". By focusing on listed companies with complete corporate governance, good growth, and scientific innovation and social influence, we will gather company leaders with extraordinary foresight and outstanding talents in the industry, gather outstanding secretaries who can continue to create value for the company, shareholders and investors, and jointly promote the high-quality development of enterprises and consolidate the "ballast stone" of comprehensively deepening the reform of the capital market ". The "Golden Quality" Sustainable Growth Award obtained by the company is an analysis of the performance of listed companies in recent years through profitability, financial status, industry position, market share, etc., and growth is an important indicator to measure the company's development prospects.
As the first listed company in China's cement industry listed on the Shanghai Stock Exchange in 1993 , and the earliest existing listed company in Zhejiang Province, Peak has maintained a good momentum of development for many years. In recent years, adhering to the strategic policy of "strengthening the main business through cooperation and innovation, standardizing science and seeking development", the company has continuously strengthened the cyclical complementary dual main business structure of cement and medicine, supplemented by health and trade logistics. In the main business, the cement industry goes out of Zhejiang, in Hubei, Guangxi, Yunnan, Guizhou and other provinces along the "Belt and Road Initiative" route, with the management and technical advantages of 60 years of deep cultivation in the cement industry combined with local raw materials and market resources, the transformation and upgrading have been effectively realized; the pharmaceutical industry has established a new drug research and development platform with the strength of academician expert workstation, postdoctoral workstation, provincial drug research and development center and well-known universities and scientific research institutes at home and abroad, and built the whole industrial chain of intermediates, raw materials and preparations. In recent years, under the turbulent economic environment at home and abroad, the company has been closely following the steady development of its main business, and its operating performance has continuously set new records. From 2016 to 2018 , the company's compound growth rate reached 43.88% , showing full development resilience and strong growth momentum. Peak stocks also passed through "bulls" and "bears" in the large cyclical fluctuations of the securities market, with accumulated cash dividends of 7.3 .1 billion yuan, giving investors good performance returns. Therefore, in this selection, the company stood out from many listed companies on the Shanghai Stock Exchange and became one of the 30 listed companies that won the "Golden Quality" Continuous Growth Award. (Reporter Fu Yiwu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page